Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc for adult nonalcoholic steatohepatitis with liver fibrosis
2014-003164-21Phase 2Completed
- Sponsor
- Allergan
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cenicriviroc in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Allergan. Primary endpoint: Hepatic histological improvement in NAFLD activity score at Year 1. Started Oct 2014; status: completed.
02
Drugs
cenicriviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2014-003164-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003164-21.